17,261 trials
Hepatitis C Infection
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 0; 66.7; 80.0; 55.6 percentage of participants
Hepatitis C Virus
Primary: Percentage of Participants With Extended Rapid Virologic Response (eRVR) — 18.0; 19.7; 25.7; 35.8 percentage of participants
Scalp Psoriasis
Primary: Percentage of Subjects With Adverse Drug Reactions (ADRs) — 3.2 percentage of participants
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Primary: Lutenising Hormone (LH) AUC(0-8) Ratio to Baseline at Day 7 — 1.118; 0.9729; 0.8804; 0.5364 Ratio
Sporadic Amyotrophic Lateral Sclerosis
Primary: Percentage of Participants That Discontinued Study Drug — 5; 32; 5 percentage of participants
Acute Heart Failure
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs and SAEs, AEs Requiring Dose Adjustment or Interruption and…
Sialorrhea Secondary to Parkinson's Disease
Primary: Sialorrhea Visual Analogue Scale (VAS) — -0.55; -1.08; -1.53; -0.81 cm on VAS — p=0.6
Healthy
Primary: Percentage of Subjects With Bactericidal Titers, BCA ≥1:4, 30 Days After the Third Immunization — 11; 11; 78; 87 Percentage of subjects
Salt-sensitive Hypertension
Primary: Cumulative Sodium Excretion (Natriuresis) at Day 1 — 61.26; 37.13; 188.87; 138.92 mmol
Bronchiectasis · Lung Disease · Respiratory Diseases
Primary: Ratio of Absolute Neutrophil Cell Count in Sputum at End of Treatment Compared to Baseline — 0.31; 1.00 ratio — p=0.004
Frailty in Aging
Primary: Safety — 4 participants
Non-Squamous Non-Small Cell Lung Cancer
Primary: Percentage of Participants Alive and Without Progressive Disease at Month 6 — 25.6; 30.0 percentage of participants
Nicotine Dependence
Primary: Number of Participants Completing Continuous Four-week Abstinence From Smoking Between the 8-week and 11-week Post Quit Day Visits — 41; 38 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Relative Change in Reactive Hyperemia Index (RHI) — 6.65; -1.27 percent change — p=0.292
Recurrent Pancreatic Carcinoma · Stage IV Pancreatic Cancer
Primary: Median Percent at Baseline and 3 Weeks in CD44+/ CD24+/ ESA+ Cells From Needle Biopsy Calculated Using FACS — 4.79; 3.09 percentage of CD44+/ CD24+/ ESA+ cells